Piper Sandler Reiterates Overweight Rating on Moderna, Inc. (MRNA)

Market Context

Moderna, Inc. operates in the Healthcare sector. The stock currently trades at $67.27 with a market capitalization of $11.6B. The stock has gained 147.7% over the past 52 weeks.

Analyst coverage from Piper Sandler provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Moderna, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Moderna, Inc.

Among the 10 most recent ratings: 2 Buy, 7 Hold, 1 Sell.

Date	Firm	Rating	Price Target
Jun 26, 2026	Piper Sandler	Overweight	N/A
Jun 08, 2026	B of A Securities	Underperform	N/A
May 04, 2026	UBS	Neutral	N/A
May 04, 2026	RBC Capital	Sector Perform	N/A
May 04, 2026	Evercore ISI Group	In-Line	N/A

Related Tools: Analyst Ratings Dashboard | View MRNA Stock Page